Новости наших партнеров

• San Diego Life Sciences Roundup: Trius, CoDa, Zacharon, & More

  09 Января 2013 Bruce V. Bigelow, Xconomy

  The annual International CES in Las Vegas again featured a Digital Health Summit, which included a number of San Diego-based startups. Rick Valencia of Qualcomm Life posted an interesting blog here, and an end-of-year report from Rock Health showed that investments in digital health startups increased more than 44 percent in 2012, to $1.4 billion from $968 million in 2011.

• CoDa Therapeutics Announces Positive Results from Phase 2b Study of NEXAGON® in Chronic Venous Leg Ulcers

  09 Января 2013

  

  CoDa Therapeutics, Inc. today announced positive results from a Phase 2b clinical trial of NEXAGON^® in patients with chronic venous leg ulcers. NEXAGON^® is an easy to administer, once-a-week, topical, drug candidate being developed for the treatment of chronic wounds. It is designed to increase the incidence of wound healing compared to existing therapeutic techniques, and to heal them much faster. The company believes these results support advancing NEXAGON into Phase 3 registration trials. Venous leg ulcers are increasingly common and costly, and can be a cause of prolonged suffering for patients.

• Square 1 Announces $6 Million Credit Facility to CoDa Therapeutics, Inc.

  06 Октября 2011

  Square 1 Bank, the exclusive banking partner to entrepreneurs and the venture capital community, is pleased to partner with CoDa Therapeutics, Inc. in providing a $6 million term loan.

• Marinus Pharmaceuticals Issued Patent for Ganaxolone

  29 Апреля 2011

  

  Marinus Pharmaceuticals, Inc., the leader in development of neurosteroids for central nervous system disorders, today announced that the United States Patent and Trademark Office (USPTO) issued the company Patent Number 7,858,609 entitled, "Solid ganaxolone formulations and methods for the making and use thereof." The patent describes a novel class of small molecules to improve stability and bioavailability of nanoparticulate formulations of ganaxolone and will provide coverage until the end of 2026.  

• CoDa Therapeutics, Inc. announced that it has raised $19.2 million in a Series B financing.

  18 Апреля 2011

  

  San Diego, California - April 18, 2011 - CoDa Therapeutics, Inc. announced today that it has raised $19.2 million in a Series B financing.

• Marinus Pharmaceuticals Announces U.S. Department of Defense Grant to Study Ganaxolone in Fragile-X Syndrome

  17 Апреля 2011

  

  Marinus Pharmaceuticals, Inc., the leader in the development of neurosteroids for central nervous system disorders, today announced the award of a $3 million grant by the U.S. Department of Defense to study its lead candidate ganaxolone for the treatment of Fragile-X Syndrome (FXS). Ganaxolone modulates GABA-A ion channels by selective binding to the neurosteroid receptor. Early research suggests that normalizing neurosteroid levels with ganaxolone treatment may eliminate the behavioral symptoms associated with FXS.